长链非编码RNA LINC00601调控肝细胞癌奥沙利铂耐药的分子机制研究

胡可舒, 刘文凤, 张锋, 权冰, 殷欣

  1. 1.复旦大学附属中山医院肝肿瘤内科,上海 200032
    2.复旦大学附属中山医院肝癌研究所,上海 200032
  • 收稿日期:2022-09-08 修回日期:2022-10-08 出版日期:2023-01-30 发布日期:2023-02-13
  • 通信作者: 殷欣
  • 作者简介:胡可舒(ORCID: 0000-0003-4576-3688),硕士。
  • 基金资助:
    国家自然科学基金(81672331)

摘要/Abstract

摘要:

背景与目的:肝细胞癌(hepatocellular carcinoma,HCC)仍是当今中国乃至全世界的高发肿瘤之一,大部分HCC患者确诊时处于中晚期,对化疗耐药或介入治疗抵抗是影响此类患者生存预后的重要因素,但其中涉及的具体分子机制尚未完全明确。我们的前期研究发现长链非编码RNA LINC00601在奥沙利铂耐药的HCC细胞中高表达。本研究旨在探索LINC00601调控HCC细胞对奥沙利铂化疗耐药的作用及其机制,为临床筛选适宜接受奥沙利铂化疗的HCC患者并为中晚期HCC患者的治疗提供新的靶点和理论依据。方法:利用体外长期低剂量奥沙利铂刺激人HCC细胞株MHCC-97H和Hep-3B,建立奥沙利铂耐药细胞株97H-OXR和3B-OXR。采用实时荧光定量聚合酶链反应(real-time fluorescence quantitative polymerase chain reaction,RTFQ-PCR)检测奥沙利铂耐药细胞株中LINC00601的表达情况。进一步采用细胞计数试剂盒-8(cell counting kit-8,CCK-8)实验检测LINC00601基因沉默或过表达对HCC细胞奥沙利铂化疗耐药的影响。通过流式细胞术和蛋白质印迹法(Western blot)检测细胞凋亡情况的变化。最后采用Western blot和免疫荧光染色检测生长阻滞和DNA损伤诱导蛋白45α(growth arrest and DNA damage-inducible protein 45α,GADD45A)的核转位,并通过RNA pull-down实验和RNA免疫共沉淀(RNA immunoprecipitation,RIP)实验验证LINC00601和GADD45A的结合。结果:与对照组细胞相比,奥沙利铂耐药细胞株中LINC00601的表达水平显著升高。奥沙利铂耐药细胞及过表达LINC00601的MHCC-97H细胞对奥沙利铂体外刺激的敏感性显著下降;相反,下调耐药细胞中LINC00601的表达后,其对于奥沙利铂体外刺激的敏感性明显提高。同时,在奥沙利铂的处理下,高表达LINC00601的HCC细胞株的凋亡水平被明显抑制,且与不同细胞株对奥沙利铂体外处理的敏感性水平相一致。此外,LINC00601的过表达使GADD45A的核转位水平降低,细胞核中GADD45A的表达下降。进一步研究发现LINC00601与GADD45A可以相互结合。结论:LINC00601可能通过调控GADD45A的核转位,进而抑制奥沙利铂处理后的细胞凋亡,导致HCC奥沙利铂耐药。

关键词: 肝细胞癌, 长链非编码RNA, 奥沙利铂, 化疗耐药

Abstract:

Background and purpose: Hepatocellular carcinoma (HCC) is still one of the most prevalent malignancies in China and throughout the world, while most of these patients are in intermediate or advanced stage when diagnosed. The resistance of advanced HCC to chemotherapy or interventional therapy is one of the crucial factors significantly limiting the survival and prognosis of patients. However, the molecular mechanisms involved have not been fully clarified. We previously found that the long non-coding RNA LINC00601 was highly expressed in oxaliplatin resistant HCC cells. This study aimed to explore the role and specific mechanism of LINC00601 in regulating the sensitivity of HCC cells to oxaliplatin chemotherapy, to provide a novel target to identify proper candidates for oxaliplatin chemotherapy, and the theoretical basis for the treatment of patients with advanced HCC. Methods: Human HCC cell line MHCC-97H and Hep-3B were induced to establish oxaliplatin resistant cell lines 97H-OXR and 3B-OXR by long-term low-dose oxaliplatin treatment in vitro. Real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR) was used to detect the expression of LINC00601 in cell lines. Cell counting kit-8 (CCK-8) assay was performed to detect the effect of LINC00601 gene silencing or overexpression on the sensitivity of HCC cells to oxaliplatin treatment. Flow cytometry and Western blot experiments were conducted to detect the alteration of cell apoptosis. Finally, Western blot and immunofluorescence staining were applied to explore the nuclear translocation of growth arrest and DNA damage-inducible protein 45α (GADD45A), and RNA pull-down together with RNA immunoprecipitation (RIP) experiments were carried out to validate the combination of LINC00601 and GADD45A. Results: Compared with the control cells, LINC00601 expression level was significantly increased in oxaliplatin resistant cells. Both induced-oxaliplatin-resistant cells and LINC00601-overexpressed MHCC-97H cells were observed to be less sensitive to oxaliplatin administration. On the contrary, the down-regulation of LINC00601 expression in oxaliplatin resistant cells significantly increased the sensitivity to oxaliplatin treatment. Meanwhile, upregulated expression of LINC00601 inhibited the apoptosis level of HCC cell lines after oxaliplatin treatment, which was consistent with the sensitivity levels of different cell lines to oxaliplatin as above. In addition, the overexpression of LINC00601 reduced the nuclear translocation of GADD45A and the expression of GADD45A in the nucleus. Furthermore, the combination of LINC00601 and GADD45A was observed. Conclusion: LINC00601 might regulate the apoptotic progress of cells after oxaliplatin chemotherapy by interfering with the nuclear translocation of GADD45A, which eventually lead to the resistance to oxaliplatin.

Key words: Hepatocellular carcinoma, Long non-coding RNA, Oxaliplatin, Chemotherapy resistance

中图分类号: 

相关文章

[1] 陈安莉, 沈浩元, 阳仕雄, 邓春燕, 胡超华, 刘汉忠, 王舒, 钱芳. 血浆长链非编码RNA H19对乳腺癌新辅助治疗效果的预测价值[J]. 中国癌症杂志, 2022, 32(8): 727-735.
[2] 廖星合, 刘占涛, 刘明辉. 脑胶质瘤干细胞衍生的外泌体lncRNA HOXA-AS2促进脑胶质瘤的增殖、迁移、侵袭和干细胞特性[J]. 中国癌症杂志, 2022, 32(12): 1218-1228.
[3] 成意财, 杜振华, 范志娟, 冯岚, 曹鹏博, 周钢桥. 血浆外泌体中的CD48蛋白作为潜在的肝细胞癌诊断标志物的研究[J]. 中国癌症杂志, 2022, 32(11): 1074-1083.
[4] 金优萍, 李录英, 周 平. 长链非编码RNA STMN1P2在乳腺癌中的作用及机制研究[J]. 中国癌症杂志, 2021, 31(7): 596-604.
[5] 郑培明, 李俊蒙, 张 鹏, 高 岚 . 巨噬细胞外泌体源miR-223促进胃癌细胞对奥沙利铂的耐药研究[J]. 中国癌症杂志, 2021, 31(5): 368-378.
[6] 肖 锋, 肖静文, 邵建国, 陈丽燕, 顾春燕 . PD-1在肝细胞癌肿瘤浸润淋巴细胞中的表达及与预后的相关性[J]. 中国癌症杂志, 2021, 31(5): 419-427.
[7] 牛 娜, 林岩松  . 90 Y微球选择性内放射治疗在肝细胞癌中的应用及研究进展[J]. 中国癌症杂志, 2021, 31(5): 428-434.
[8] 刘 敏, 陈添亮, 郭 娟, 伊  雪, 高洪泉, 巫佳翠, 王玉孝 . 蛋白激酶CβⅡ通过IL-6自分泌途径促进肝细胞癌侵袭的研究[J]. 中国癌症杂志, 2021, 31(4): 268-276.
[9] 章 俊, 董宇华, 杨 叶, 张梦琪, 何 常 . Regorafenib联合TAS102新策略治疗肝细胞癌的研究[J]. 中国癌症杂志, 2021, 31(4): 294-301.
[10] 张 欣, 周 成, 周恺乾, 柏乾明, 蒋冬先, 宿杰阿克苏, 侯英勇, 王 征, 纪 元 . 肉瘤样肝细胞癌中MET基因扩增与预后的相关性分析[J]. 中国癌症杂志, 2020, 30(9): 641-649.
[11] 徐珊珊 , 宋琴琴 , 仵红娇 , 付 宁 , 车玲玉 , 金 敏 , 刘 冲 , 韩素桂 , 张雪梅 , 张 志 . 膜辅助蛋白CD46 rs1970530遗传变异对肝癌发病风险的影响[J]. 中国癌症杂志, 2020, 30(9): 656-660.
[12] 皮思蝶, 郑小川, 毛彬力, 崔 静, 胡 源. SAMHD1通过调控p27表达抑制肝细胞癌细胞增殖的研究[J]. 中国癌症杂志, 2020, 30(7): 489-496.
[13] 张良龙 , 安宏伟 , 赵立智 , 董 倩 , 高桂艳 . LncRNA LINC00152过表达在替莫唑胺诱导脑胶质瘤干细胞周期阻滞中的作用机制探讨[J]. 中国癌症杂志, 2020, 30(5): 328-334.
[14] 蒙秋华, 田 婧, 覃 妍, 蒙秋晓, 董 敏. 蛋白酪氨酸磷酸酶受体D通过STAT3途径影响肝癌细胞PD-L1表达的机制研究[J]. 中国癌症杂志, 2020, 30(4): 261-267.
[15] 程 淇, 易晓芳  . 铁死亡在肿瘤耐药中作用的研究进展[J]. 中国癌症杂志, 2020, 30(2): 148-153.